» Articles » PMID: 34518829

Endothelial Dysfunction and Its Critical Role in COVID-19-associated Coagulopathy: Defibrotide As an Endothelium-protective, Targeted Therapy

Overview
Journal EJHaem
Specialty Hematology
Date 2021 Sep 14
PMID 34518829
Citations 2
Authors
Affiliations
Soon will be listed here.
Citing Articles

Endothelial activation and damage as a common pathological substrate in different pathologies and cell therapy complications.

Palomo M, Moreno-Castano A, Salas M, Escribano-Serrat S, Rovira M, Guillen-Olmos E Front Med (Lausanne). 2023; 10:1285898.

PMID: 38034541 PMC: 10682735. DOI: 10.3389/fmed.2023.1285898.


Defibrotide Therapy for SARS-CoV-2 ARDS.

Frame D, Scappaticci G, Braun T, Maliarik M, Sisson T, Pipe S Chest. 2022; 162(2):346-355.

PMID: 35413279 PMC: 8993696. DOI: 10.1016/j.chest.2022.03.046.

References
1.
Richardson P, Carreras E, Iacobelli M, Nejadnik B . The use of defibrotide in blood and marrow transplantation. Blood Adv. 2018; 2(12):1495-1509. PMC: 6020812. DOI: 10.1182/bloodadvances.2017008375. View

2.
Goshua G, Pine A, Meizlish M, Chang C, Zhang H, Bahel P . Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol. 2020; 7(8):e575-e582. PMC: 7326446. DOI: 10.1016/S2352-3026(20)30216-7. View

3.
Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis T, Politou M . Hematological findings and complications of COVID-19. Am J Hematol. 2020; 95(7):834-847. PMC: 7262337. DOI: 10.1002/ajh.25829. View

4.
Levi M, Iba T . COVID-19 coagulopathy: is it disseminated intravascular coagulation?. Intern Emerg Med. 2020; 16(2):309-312. PMC: 7758412. DOI: 10.1007/s11739-020-02601-y. View

5.
Buijsers B, Yanginlar C, Maciej-Hulme M, de Mast Q, van der Vlag J . Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients. EBioMedicine. 2020; 59:102969. PMC: 7445140. DOI: 10.1016/j.ebiom.2020.102969. View